Prostate Cell News Volume 11.07 | Feb 28 2020

TOP STORY

Macropinocytosis Confers Resistance to Therapies Targeting Cancer Anabolism

Necrotic cell debris allowed macropinocytic breast and prostate cancer cells to proliferate, despite fatty acid synthase inhibition. [Nat Commun] Full Article

(Ranked by impact factor of the journal)

P-REX1-Independent, Calcium-Dependent RAC1 Hyperactivation in Prostate Cancer

Scientists demonstrated that aggressive androgen-independent prostate cancer cells displayed marked hyperactivation of Rac1. This hyperactivation was independent of P-Rex1 activity or its direct activators, the PI3K product PIP₃ and Gβγ subunits. [Cancers] Full Article

Bifunctional Au-Templated RNA Nanoparticles Enable Direct Cell Uptake Detection and GRP75 Knockdown in Prostate Cancer

The release of gold (Au)-functionalized siRNA particles in prostate cancer cells resulted in concomitant knockdown of GRP75, which led to detectable levels of cell death in the absence of a transfection vector. [J Mater Chem B] Abstract | Graphical Abstract

Targeting STAT3 Enhances NDV-Induced Immunogenic Cell Death in Prostate Cancer Cells

Researchers showed that Newcastle disease virus (NDV)/FMW, an oncolytic NDV strain FMW, elicited the expression and release of several immunogenic cell death markers in prostate cancer cells. [J Cell Mol Med] Full Article

Hexane Insoluble Fraction From Purple Rice Extract Retards Carcinogenesis and Castration-Resistant Cancer Growth of Prostate through Suppression of Androgen Receptor Mediated Cell Proliferation and Metabolism

In LNCaP and PCai1 cells, a hexane insoluble fraction from a purple rice ethanolic extract treatment suppressed cell proliferation and induced G0/G1 cell-cycle arrest. [Nutrients] Full Article | Graphical Abstract

Combined Targeting of EGFR and HER2 against Prostate Cancer Stem Cells

Scientists investigated the efficacy of a dual intervention against EGFR and HER2 to deplete tumor-initiating cells, optimize chemotherapy management and prevent the progression of castration-resistant prostate cancer cells. [Cancer Biol Ther] Abstract

Knockdown of lncRNA CCAT1 Enhances Sensitivity of Paclitaxel in Prostate Cancer via Regulating miR-24-3p and FSCN1

Paclitaxel (PTX)-resistant prostate cancer (PCa) cells were established in PC3 and DU145 cells by increasing concentrations of PTX. Researchers showed that the expressions of colon cancer-associated transcript 1 (CCAT1) were up-regulated and miR-24-3p was down-regulated in PCa and PTX-resistant PCa cells. [Cancer Biol Ther] Full Article

Metabolomic Analysis of Morus Cultivar Root Extracts and Their Ameliorative Effect on Testosterone-Induced Prostate Enlargement in Sprague-Dawley Rats

LNCaP cells were used to evaluate the prostate-specific antigen inhibitory activity of Morus roots, and, amongst them, the extract with the highest activity was selected. [Int J Mol Sci] Full Article

Isolation and Characterization of Flavonoid Derivatives with Anti-Prostate Cancer and Hepatoprotective Activities from the Flowers of Hosta plantaginea (Lam.) Aschers

The chemicals of H. plantaginea (Lam.) Aschers were evaluated for their anti-prostate cancer activities using the LNCaP prostate cancer cells. [J Ethnopharmacol] Abstract

Long Noncoding RNA PRRT3-AS1 Silencing Inhibits Prostate Cancer Cell Proliferation and Promotes Apoptosis and Autophagy

Scratch test, Transwell assay, CCK-8 assay, colony formation assay, flow cytometry and Monodansylcadaverine staining were applied to identify the migration, invasion, proliferation activity, cell cycle and apoptosis and autophagy of PC3 cells. [Exp Physiol] Abstract | Graphical Abstract

Subscribe to one of our other 19 science newsletters such as Mammary Cell News & ESC & iPSC News.

All Change in the Prostate Cancer Diagnostic Pathway

The authors describe the current diagnostic pathway for prostate cancer, which relies on nontargeted biopsies, and the problems linked to this pathway. [Nat Rev Clin Oncol] Abstract

Tumor Metabolism and Its Unique Properties in Prostate Adenocarcinoma

The distinct metabolic aberrations in prostate adenocarcinoma are driven by the androgen receptor, providing opportunities for functional metabolic imaging and novel therapeutic interventions that will be complementary to existing diagnostic and treatment options. [Nat Rev Urol] Abstract

Considering the Role of Radical Prostatectomy in 21st Century Prostate Cancer Care

The changing demographics of prostate cancer means that radical prostatectomy remains an important and useful option in many men, with a changing indication. [Nat Rev Urol] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

Veru Initiates Phase II Clinical Trial of VERU-111, First-in-Class, Oral, Advanced Prostate Cancer Drug

Veru, Inc. announced that it has initiated the Phase II portion of its ongoing Phase Ib/II clinical trial for VERU-111, its first-in-class, oral, selective antitubulin proprietary drug for metastatic castration and novel androgen blocking agent resistant prostate cancer. [Veru, Inc.] Press Release

UCLA Raises $5.49 Billion in One of Most Ambitious Campaigns Ever by a Public University

The Centennial Campaign for University of California, Los Angeles (UCLA) has raised $5.49 billion. As UCLA enters its second century, the funds are already supporting a broad array of priorities, including student scholarships and fellowships, faculty research, and programs that enrich communities in Los Angeles and beyond. [University of California, Los Angeles] Press Release

Federal Judge Rules Clinical Trial Sponsors Must Publish a Decade’s Worth of Missing Data

For years, government research agencies have misinterpreted a law that requires them to collect and post clinical trial data, a federal judge ruled this week, leaving behind a ten year gap in data that now must be made publicly available. [STAT News] Editorial

Contract Offers Unprecedented Look at Google Deal to Obtain Patient Data from the University of California

It was the fall of 2015 when researchers from Google and the University of California, San Francisco, first sat down together to hash out a research collaboration in an area that has since exploded with activity: using artificial intelligence to make predictions in the hospital. [STAT News] Editorial

NEW Gordon Research Conference: Tissue Stem Cell Regulation by Autonomous and Non-Autonomous Mechanisms
July 12-17, 2020
Ventura, California, United States

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Researcher – Cellular Metabolism and Metabolic Regulation (Flanders Institute for Biotechnology)

NEW Head – Single Cell Research (Sloan Kettering Institute)

Senior Laboratory Research Scientist – Autophagy in Cancer (The Francis Crick Institute)

Postdoctoral Studentship – Stress Signaling and Prostate Cancer (University of Oslo)

Postdoctoral Fellow – Prostate Tumorigenesis (University of Cincinnati)

Postdoctoral Fellow – RNA Splicing in Cancer (The University of Texas MD Anderson Cancer Center)

Postdoctoral Position – Organoid Models of Prostate Cancer (University of Freiburg)

Postdoctoral Position – Cancer Cell Competition (Albert Einstein College of Medicine)

Postdoctoral Fellow – Cancer Biology (City of Hope)

Postdoctoral Fellow – Translational Cancer Research (University of New Mexico)

Postdoctoral Researcher – Chromatin Structures in Cancer Cell States (Medical University of Gdańsk)

Tenure-Track Faculty Scientist Position – Radiation Oncology (New York University)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.